The main aim of this study is to collect more information on the effectiveness of TDV when used in a pilot public vaccination program for children and adolescents participating in a community-based cohort in Southeast Asian countries with high dengue transmission, specifically Thailand, Indonesia, and Malaysia where TDV is already approved for use. The study will include cohort participants (individual follow-up of 3 years) who may or may not later be vaccinated with TDV as part of a pilot public vaccination program in the study countries. The study will investigate if cohort participants who were vaccinated with TDV have less hospital stays due to dengue than cohort participants who were not vaccinated with TDV. The study will also provide further information on the effectiveness of TDV against the least common dengue virus serotypes (DENV-3 and DENV-4).
Study Type
OBSERVATIONAL
Enrollment
70,000
This is a non-interventional study.
Fakultas Kedokteran Lambung Mangkurat
Banjarmasin, South Kalimantan, Indonesia
RECRUITINGFakultas Kedokteran Universitas Sriwijaya
Palembang, South Sumatra, Indonesia
RECRUITINGFakultas Kedokteran Universitas Indonesia
Jakarta Pusat, Indonesia
RECRUITINGUniversiti Malaya Medical Centre
Kuala Lumpur, Malaysia
NOT_YET_RECRUITINGPattaya Patamakhun Hospital
Chon Buri, Thailand
ACTIVE_NOT_RECRUITINGNakhon Phanom Hospital
Nakhon Phanom, Thailand
ACTIVE_NOT_RECRUITINGPhra Nakhon Si Ayutthaya Hospital
Phra Nakhon Si Ayutthaya, Thailand
ACTIVE_NOT_RECRUITINGHospitalization Due to VCD of Any Dengue Serotype in Unvaccinated and Fully Vaccinated Participants
Number of participants hospitalized due to VCD of any dengue serotype in unvaccinated and fully vaccinated participants.
Time frame: Up to Month 36
Hospitalization Due to VCD By Each Infecting Dengue Serotype (DENV-1, DENV-2, DENV-3, DENV-4) in Unvaccinated and Fully Vaccinated Participants
Number of participants hospitalized due to VCD with each infecting dengue serotype (dengue virus \[DENV\]-1, DENV-2, DENV-3, and DENV-4) in unvaccinated and fully vaccinated participants will be reported.
Time frame: Up to Month 36
Hospitalization Due to VCD by Baseline Dengue Serostatus (Seronegative and Seropositive) of Any Dengue Serotype in Unvaccinated and Fully Vaccinated Participants
Number of participants hospitalized due to VCD with dengue serostatus (seronegative and seropositive) of any dengue serotype in unvaccinated and fully vaccinated participants will be reported.
Time frame: Up to Month 36
Hospitalization Due to VCD By Each Infecting Dengue Serotype and Baseline Dengue Serostatus in Unvaccinated and Fully Vaccinated Participants
Number of participants hospitalized due to VCD by each infecting dengue serotype and baseline dengue serostatus (DENV-1 in baseline seronegative, DENV-2 in baseline seronegative, DENV-3 in baseline seronegative, DENV-4 in baseline seronegative, DENV-1 in baseline seropositive, DENV-2 in baseline seropositive, DENV-3 in baseline seropositive, and DENV-4 in baseline seropositive) in unvaccinated and fully vaccinated participants will be reported.
Time frame: Up to Month 36
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.